Please assess the completion status of the following clinical trial:

Trial Title: Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
* Patient has confirmed clinical diagnosis of SMM according to a definition derived from the International Myeloma Working Group (IMWG) definition: serum M-protein ≥3 g/dL or bone marrow clonal plasma cells (BMPC) greater than or equal to 10%, or both, along with normal organ and marrow function (CRAB) within 4 weeks before baseline.~* C: Absence of hypercalcemia, evidenced by a calcium \<10.5 mg/dL.~* R: Absence of renal failure, evidenced by a creatinine \<2.0 mg/dL or calculated creatinine clearance (using the Modification of Diet in Renal Disease \[MDRD\] formula) \>50 mL/min.~* A: Absence of anemia, evidenced by a hemoglobin \>10 g/dL.~* B: Absence of lytic bone lesions on standard skeletal survey.~* Patient is at higher than average risk of progression to active MM, defined as having 2 or more of the following features:~* Serum monoclonal (M)-protein ≥3 g/dL.~* BMPC greater than or equal to 10%.~* Abnormal serum free light chain (FLC) ratio (0.26-1.65).~* Patient has a life expectancy of greater than 6 months~* Patient is human leukocyte antigen (HLA)-A2 positive.~* Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.~* Patient has adequate bone marrow function, evidenced by a platelet count ≥75×109/L and an absolute neutrophil count (ANC) ≥1.0×109/L within 2 weeks before baseline.~* Patient has adequate hepatic function, evidenced by a bilirubin ≤2.0 mg/dL and an alanine transaminase (ALT), and aspartate transaminase (AST) ≤2.5× the upper limit of normal (ULN) within 2 weeks before baseline.~* If of child-bearing potential, patient agrees to use adequate birth control measures during study participation.~* If a female of child-bearing potential, patient has negative urine pregnancy test results within 2 weeks before baseline and is not lactating.~* Patient (or his or her legally accepted representative) has provided written informed consent to participate in the study.~Exclusion Criteria:~* Patient has symptomatic multiple myeloma, as defined by any of the following:~* Lytic lesions or pathologic fractures.~* Anemia (hemoglobin \<10 g/dL).~* Hypercalcemia (corrected serum calcium \>11.5 mg/dL).~* Renal insufficiency (creatinine \>2 mg/dL).~* Other: symptomatic hyperviscosity, amyloidosis.~* Patient has abnormal cardiac status, evidenced by any of the following:~* New York Heart Association (NYHA) stage III or IV congestive heart failure (CHF).~* Myocardial infarction within the previous 6 months.~* Symptomatic cardiac arrhythmia requiring treatment or persisting despite treatment.~* Patient is receiving any other investigational agent.~* Patient has a current active infectious disease or positive serology for human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV).~* Patient has a history of or current auto-immune disease.~* Patient has been vaccinated with live attenuated vaccines within 4 weeks before study vaccination.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- PVX-410, .4 mg dose (Type: EXPERIMENTAL): Approximately 3 patients will receive 6, bi-weekly, subcutaneous injections of a .4 mg dose of PVX-410 in combination with an intramuscular injection of Hiltonol (poly ICLC). Patients will complete a 12 week treatment phase and then will be followed for safety, immunogenicity and clinical response for 12 months.
- PVX-410, .8 mg dose (Type: EXPERIMENTAL): Approximately 10 patients will receive 6, bi-weekly, subcutaneous injections of an .8 mg dose of PVX-410 in combination with an intramuscular injection of Hiltonol (Poly ICLC). Patients will complete a 12 week treatment phase and then will be followed for safety, immunogenicity and clinical response for 12 months.
- PVX-410 plus lenalidomide (Type: EXPERIMENTAL): Approximately 10 patients will receive 6, bi-weekly, subcutaneous injections of an .8 mg dose of PVX-410 in combination with an intramuscular injection of Hiltonol (Poly ICLC). Patients will also receive 3 cycles of lenalidomide. Patients will complete a 12 week treatment phase and then will be followed for safety, immunogenicity and clinical response for 12 months

Based on this trial design, predict the completion outcome and termination type (if applicable).